and Produce Biologically Advanced Materials
Modern Meadow is a dedicated team of individuals guided by a collective belief: biofabrication unlocks the power of nature to offer new design possibilities. Everything we do is rooted in human ingenuity’s ability to make tomorrow better than today.
A pioneer of biofabrication, we believe that multidisciplinary collaboration between design, biology and material science can lead to smarter ways to make evolved materials. We partner with thought-leading brands to transform the material world and design for a healthier planet.
Co-founder and Chief Executive Officer
Andras co-founded Modern Meadow in 2011 and is leading the company into a new age of biofabrication. Andras is also co-founder of 3D bioprinting company Organovo. Previously, he held positions with an international technology-focused venture fund, McKinsey & Co. and Citigroup. Andras is founding chairman of the international non-profit Resolution Project and was a Kauffman Fellow with the Center for Venture Education. He holds an MBA from The Wharton School and a Bachelor of Arts with honors from Harvard.
Chief Business Officer
Rachel Mears comes to Modern Meadow as its Chief Business Officer and General Counsel where she is responsible for the corporate development, commercialization and marketing, and legal functions for the company. A business executive with two decades of experience in the life sciences and consumer products industry, she led strategy and international business operations for Forest Laboratories, a U.S. based pharmaceutical company (now a part of Allergan) and most recently was Chief of Staff to the General Counsel at PepsiCo. Rachel, who is passionate about delivering innovation to the market, received a B.S. in Chemistry from Stanford University and J.D. from New York University School of Law.
Chief Technology Officer
Dave, Modern Meadow’s Chief Technology Officer, began his career at Kraton Polymers before spending over a decade at DuPont, where he was most recently the Chief of Staff for the Office of the Chief Science and Technology Officer. He holds a PhD in Chemistry from Virginia Polytechnic Institute and State University and a Bachelor of Science in Chemistry from Virginia Commonwealth University.
VP, Business Development
Susan is an experienced product development leader with over a dozen years of industry experience in biotechnology and materials. For this sector, she has developed and commercialized new materials and formed strategic partnerships, delivering products from initial ideation to market. Susan received her bachelor’s degree in chemistry from Brown University and her PhD in organometallic and inorganic chemistry from Caltech. She was a National Science Foundation International Postdoctoral Fellow at Stockholm University and Uppsala University.
Rex is a finance and accounting leader with over 15 years of experience working with and at emerging and high-growth manufacturing companies. Most recently, Rex was part of the team that took Tesla public as well as implemented the financial systems to support the Model S launch. Prior to that, he supported the financial growth of Gilead Sciences from $870 million to $7 billion in revenues. A CPA, Rex began his career at Ernst & Young. He received his honors bachelor’s degree in immunology as well as an MBA from the University of Toronto.
Luck is an experienced people leader, with over 15 years of experience in Human Resources and Account Management across the technology, finance and pharmaceutical advertising industries. Prior to joining Modern Meadow, she held positions at Spotify, Compass, LimeWire, and Flatiron Health. Luck is an iPEC-trained professional coach and a trusted HR professional, coach, confidante and advisor.
To learn more about our employment opportunities, email email@example.com.
Board of Directors
Anna Bakst is Chief Executive Officer and Brand President, Kate Spade. In this role, she is responsible for leading all aspects of the brand with a focus on driving global expansion and innovation. Ms. Bakst has over 25 years of experience managing and growing global fashion brands. Until January 2017, she served as Michael Kors, Group President of Accessories and Footwear where she led the global design, production and merchandising teams, as well as domestic wholesale distribution. Prior to Michael Kors, Ms. Bakst had a 12-year career at Donna Karan International where she held various positions including President of Accessories and Footwear. Ms. Bakst received an MBA from Stanford University and a BS in Industrial Engineering from Purdue University. She is also an Associate Professor at Pratt Institute's Design Management program.
Bart Swanson is currently an advisor to Horizon Ventures, a venture capital firm based in Hong Kong with a focus on disruptive technologies. Mr. Swanson is on the boards of Zoom Video Communications Inc., Impossible Foods, Sentient Technologies, Benevolent AI, Hola Networks, Leo Labs Inc, and several other technology companies in Europe, Israel, and the US. Bart was previously a director at Onavo, DeepMind, Bitstrips, Crosswise.com, Viv and from 2015-17 a non-executive board member at MTG AB. Bart received an MBA from The Wharton School and an MA in International Studies from the University of Pennsylvania. He was a Fellow at the Lauder Institute and has a BA in History from the University of Southern California.
David Evans Shaw is Managing Partner of Black Point Group, with wide-ranging interests in technology companies and public service. His business creation, leadership, investment and board experience includes IDEXX Laboratories, Ikaria Pharmaceuticals, Itaconix, Skinetics, Cyteir, Cytyc, Physion, Venrock Associates, MyTaskIt, New Mountain Capital, Polaris Venture Partners, the film Second Century Stewardship, and others. He has also served as a strategy consultant to consumer products, food and agribusiness companies.
Dr. Fenton brings more than forty years of experience in biopharmaceutical drug development and commercialization to this position. During a 25-year tenure at Amgen, he served as executive vice president of operations and held numerous additional executive leadership roles in operations, process development, sales, marketing, research, engineering and manufacturing. Since retiring from Amgen in 2008, Dr. Fenton has served as an independent biotechnology consultant and serves on several public and private company boards including Portola Pharmaceuticals, Pfenex, Sienna Biopharmaceuticals, and Omniox. Dr. Fenton previously served on the boards of directors of Kythera, Amira, Hospira, Dendreon Corp., Xenoport and Genzyme Corporation. He is also a member of the board of trustees of the Keck Graduate Institute. Dr. Fenton received a Bachelor of Science in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.
Gabor is a theoretical physicist turned bioengineer, innovator and entrepreneur. A pioneer in building living structures using bioprinting, Gabor is the scientific founder of Organovo and Modern Meadow. The technologies he has developed have been applied to drug development and testing and tissue engineering of biomaterials. He is the George H. Vineyard Professor Emeritus of Biological Physics at the University of Missouri-Columbia and Scientific Director of the Shipley Centre for Innovation at Clarkson University. He was trained as a physicist at the Roland Eotvos University, Budapest, Hungary. He also has a degree in biology. Gabor has been recognized by numerous awards, in particular, he was named as one of the "100 most innovative people in business in 2010" by FastCompany.